The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem‐cell transplantations: A single‐center experience
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15366 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Utku Aygüneş und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology-Oncology & Bone Marrow Transplantation, Acibadem Adana Hospital, Adana, Turkey. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Transplantation, Homologous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
In children with high‐risk childhood acute leukemia who undergo allogeneic hematopoietic stem‐cell transplantation (allo‐HSCT), relapse is still the leading cause of treatment failure. The prognosis is poor, yet prospective studies have only limited data on risk factors and outcomes. We aimed to understand the outcomes and prognostic factors for patients with acute lymphoblastic leukemia (ALL) who relapsed following allo‐HSCT. We analyzed retrospectively 46 children with childhood acute lymphoblastic leukemia who had relapsed after receiving their first alloHSCT. All these patients received salvage chemotherapy which consisted of fludarabine, cytarabine, and idarubicin before performing a second alloHSCT. The median follow‐up of the 46 patients after the first transplantation was 366 days. The median time from first allo‐HSCT to relapse was 278.4 ± 238.4 days. Forty‐six patients received salvage chemotherapy before the second alloHSCT, and CR was achieved in 32 of 46 patients. However, only 17 (37%) of 46 patients received a second allo‐HSCT, and 15 of 46 patients died from disease progression, infections, and bleeding. Twelve patients are still alive after the second allo‐HSCT. Two‐year overall survival (OS) was 38.9%. Local therapy was given to 10 (21.8%) patients, either as part of systemic therapy or alone. In multivariate analyses, the time of relapse and curative salvage therapy with a second allo‐HSCT were identified as significant prognostic factors for OS. Children with leukemia who had relapsed after the first allo‐HSCT received salvage chemotherapy. Our statistical analysis showed that the second HSCT could be beneficial for outcomes if patients relapsed beyond 180 days of the first allo‐HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Hematology-Oncology & Bone Marrow Transplantation, Acibadem Adana Hospital, Adana, Turkey.
- Department of Pediatric Hematology-Oncology, Adana City Training and Research Hospital, Adana, Turkey.
ORCID-Profile: Utku Aygüneş, Barbaros Şahin Karagün, Ilgen Şaşmaz, Ali Bülent Antmen
Zitieren
APA
Aygüneş, U., Karagün, B. Ş., Şaşmaz, I., & Antmen, A. B. (2024). The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem‐cell transplantations: A single‐center experience. Clinical Transplantation. https://doi.org/10.1111/ctr.15366
Vancouver
Aygüneş U, Karagün BŞ, Şaşmaz I, Antmen AB. The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem‐cell transplantations: A single‐center experience. Clinical Transplantation. 2024. doi:10.1111/ctr.15366
BibTeX
@article{Aygne2024,
author = {Aygüneş, Utku and Karagün, Barbaros Şahin and Şaşmaz, Ilgen and Antmen, Ali Bülent},
title = {The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem‐cell transplantations: A single‐center experience},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15366}
}
EUVIMED